These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31069147)

  • 1. Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines.
    Perez Horta Z; Saseedhar S; Rakhmilevich AL; Carmichael L; Hank JA; Boyden M; Gillies SD; Sondel PM
    Oncoimmunology; 2019; 8(6):e1238538. PubMed ID: 31069147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.
    Gubbels JA; Gadbaw B; Buhtoiarov IN; Horibata S; Kapur AK; Patel D; Hank JA; Gillies SD; Sondel PM; Patankar MS; Connor J
    Cancer Immunol Immunother; 2011 Dec; 60(12):1789-800. PubMed ID: 21792658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity.
    Gillies SD
    Protein Eng Des Sel; 2013 Oct; 26(10):561-9. PubMed ID: 24025193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral immunocytokine treatment results in enhanced antitumor effects.
    Johnson EE; Lum HD; Rakhmilevich AL; Schmidt BE; Furlong M; Buhtoiarov IN; Hank JA; Raubitschek A; Colcher D; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Immunol Immunother; 2008 Dec; 57(12):1891-902. PubMed ID: 18438664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
    Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
    Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
    Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
    Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma.
    Nguyen R; Zhang X; Sun M; Abbas S; Seibert C; Kelly MC; Shern JF; Thiele CJ
    Clin Cancer Res; 2022 Sep; 28(17):3785-3796. PubMed ID: 35802683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
    Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
    Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Contribution of IL2Rγ to the Dynamic Formation of IL2-IL2R Complexes.
    Ponce LF; García-Martínez K; León K
    PLoS One; 2016; 11(5):e0155684. PubMed ID: 27195783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model.
    Baniel CC; Sumiec EG; Hank JA; Bates AM; Erbe AK; Pieper AA; Hoefges AG; Patel RB; Rakhmilevich AL; Morris ZS; Sondel PM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 2 receptors on squamous cell carcinomas of the head and neck. Characterization and functional role.
    Cortesina G; Sacchi M; Galeazzi E; Johnson JT; Whiteside TL
    Acta Otolaryngol; 1992; 112(2):370-5. PubMed ID: 1605010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble interleukin 2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with interleukin 5.
    Loughnan MS; Sanderson CJ; Nossal GJ
    Proc Natl Acad Sci U S A; 1988 May; 85(9):3115-9. PubMed ID: 3129727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
    Wieckowski S; Hemmerle T; Prince SS; Schlienger BD; Hillinger S; Neri D; Zippelius A
    Lung Cancer; 2015 Apr; 88(1):9-15. PubMed ID: 25682318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining computational and experimental biology to develop therapeutically valuable IL2 muteins.
    León K; García-Martínez K; Carmenate T; Rojas G
    Semin Oncol; 2018 Jan; 45(1-2):95-104. PubMed ID: 30318089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R.
    Harvill ET; Morrison SL
    Immunotechnology; 1995 Aug; 1(2):95-105. PubMed ID: 9373338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of interleukin 2 receptor beta chain in initiating anti-CD3 and interleukin 2-induced proliferation of human resting T cells.
    Moiré N; Calvo CF; Métivier D; Perrot JY; Vaquero C; Hatakeyama M; Senik A
    Eur J Immunol; 1990 Sep; 20(9):1981-7. PubMed ID: 2145171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new bioassay for the immunocytokine L19-IL2 for simultaneous analysis of both functional moieties.
    Winter J; Barbin K; Bacci C; Bunte T
    J Pharm Biomed Anal; 2011 Jan; 54(1):81-6. PubMed ID: 20828971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.
    Sondel PM; Gillies SD
    Antibodies (Basel); 2012 Jul; 1(2):149-171. PubMed ID: 24634778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
    Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer.
    Connor JP; Felder M; Hank J; Harter J; Gan J; Gillies SD; Sondel P
    J Immunother; 2004; 27(3):211-9. PubMed ID: 15076138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.